An Indian pharmaceutical company announced Friday it will dramatically expand its workforce next year, adding more than 700 new positions as global demand for drug manufacturing services continues to surge.
Sai Life Sciences revealed plans to grow its employee base by approximately 20% during the upcoming financial year, bringing new jobs to meet increasing international orders. The company currently maintains a workforce of roughly 3,400 people spread across facilities in India, the United States, and the United Kingdom.
The pharmaceutical firm generates the majority of its revenue from clients in America, Europe, and Britain, positioning it well to capitalize on the industry’s current expansion.
This workforce expansion reflects broader trends in India’s pharmaceutical sector, which has experienced rapid growth as international drug companies increasingly relocate high-value operations to the country. Companies are drawn by India’s lower production costs, skilled workforce, and efforts to diversify their supply chains beyond traditional markets.
Industry analysts project significant growth ahead for India’s contract drug research and manufacturing sector, with market research firm Mordor Intelligence forecasting the industry will more than double to reach $57.94 billion between 2025 and 2031.
The new positions at Sai Life Sciences will focus on scientific, technical, and management roles based in Hyderabad, a major southern Indian city. The company operates its primary research and development facility there, supporting drug development projects, data-driven drug discovery efforts, and large-scale commercial manufacturing operations.
Company CEO and Managing Director Krishna Kanumuri described the expansion as part of ongoing “global supply-chain rebalancing” taking place across the pharmaceutical industry.
Over the past six years, Sai Life Sciences has committed more than $219 million toward expanding its manufacturing capabilities to support this growth strategy.
